What this study is
The goal of this clinical trial is to learn if a device which provides vagal nerve stimulation, applied to the tragus of the ear via an ear clip, can improve sleep in individuals recovering from stroke while they are treated in a rehabilitation hospital. The main questions this study aims to answer are:
1. Does using this device improve insomnia? 2. Does this device have any impact on the person's stroke severity, mobility, self-care, or ability to think? Researchers will compare this treatment to a sham (a look-alike device that will not deliver the stimulation).
Participants will:
- Complete questionnaires about insomnia and their ability to think
- Use the device for 30 minutes every evening for at least 10 nights during their inpatient stay
- Complete a log tracking their use of the device and any concerns
What's being tested
- transauricular Vagal Nerve Stimulation
Intervention · DEVICE
All participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London). Participants will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. Stimulation parameters will be set at 200µs pulse width (with proprietary waveform) and 20Hz. The intensity will be set to level 21 and increased up to 32 as tolerated, but reduced sequentially to intensity level 12 if unable to tolerate due to discomfort. They will include amplitudes 1.0-1.7mA for therapeutic thresholds.
- Sham Comparator
Intervention · DEVICE
All participants will be instructed around the use of the non-invasive taVNS Parasym device (by Parasym Ltd., London). Participants will be instructed to utilize the Parasym device for 30min daily between 7-9pm for at least 10 days following. Stimulation parameters will be set to the same parameters as for the experimental group, however his device will include a sham earpiece that will prevent the transmission of taVNS.
Study details
- Official title
- The Impact of Vagus Nerve Stimulation on Improving Sleep for Individuals in an Inpatient Rehab Facility for Post-Acute Ischemic Stroke
- Sponsor
- Casa Colina Hospital and Centers for Healthcare
- Conditions
- Stroke · Ischemic Cerebrovascular Accident · Ischemic Stroke · Vagal Nerve Stimulation
- Enrolling
- 52 people
- Starts
- 2026-10-16
- Est. completion
- 2027-12-16
- Design
- Double-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Admitted to Casa Colina's acute rehabilitation service
- Diagnosis of ischemic stroke
- Age 18 years or older
- English or Spanish speaking
- Sufficient cognition to follow program instructions tested Mini Mental Exam (score >17/30)
- Confirmed sleep abnormalities based on the Insomnia Severity Index (ISI) meeting criteria for subthreshold or clinical insomnia (score >7/28)
You can't join if
- Hemorrhagic stroke or hemorrhagic conversion of ischemic stroke
- Other confirmed neurological diagnoses
- Previous surgical intervention on the vagus nerve
- Any open wound or cancerous lesions at the ear within 1 inch of the ear tragus
- Contraindication to the device, including patients with severe bradycardia, patients with a permanent implanted metallic or electronic device or jewelry at close proximity (2cm) to the ear tragus, patients with a recent (within 1 year) history of trigeminal neuralgia, pregnancy
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openCasa Colina Hospital and Centers for Healthcare
Pomona, California, United States
- Niko Fullmer · Contact9095967733 ext. 2220NFullmer@casacolina.org
- Emily Rosario, PhD · Contact9095967733 ext. 3316ERosario@casacolina.org
- Marie Yeseta, PT, DPT, NCS · Principal investigator
Recruiting
Study team
Sponsor
Casa Colina Hospital and Centers for Healthcare
Study ID SleepVNS
Study director
Emily Rosario, PhD
Casa Colina Hospital and Centers for Healthcare
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.